2nd Innovation in Obesity Therapeutics Summit
The obesity therapeutics landscape is undergoing a radical expansion, fueled by groundbreaking late-stage trials for Novo Nordisk's amycretin and Metsera's exciting early data for its amylin-targeting shot. This new era of innovation promises wider accessibility and improved patient outcomes, making the 2nd Innovation in Obesity Therapeutics Summit the essential forum for accelerating the next wave of treatment.
Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Boehringer Ingelheim, as well as innovative biotechs like Veru, Supercede Therapeutics, and Rivus Pharmaceuticals, who will share their groundbreaking research and strategies. The pressure is on to continue work on developing best-in-class treatments that transform patient lives.
Where: DoubleTree by Hilton Hotel San Diego - Mission Valley
When: December 2-4, 2025
Program: https://ter.li/n2scpy
Don't miss this pivotal opportunity to network with 60+ leading scientists and drug development experts in the field of obesity, forge crucial collaborations, and be part of the solution. The future of obesity therapeutics is being written now – be a part of it!
Visit the full agenda and speakers here: https://ter.li/n2scpy
